EP. 1: Existing Treatment Landscape of Immunotherapies
EP. 2: Clinical Insights on Newer Immunotherapies in Lung Cancer
EP. 3: Immunotherapy in Oncology and the Role of the PD-L1 Biomarker
EP. 4: Early Biomarkers and Coverage Decisions in Immuno-Oncology
EP. 5: How Important Are Biomarkers for Treatment Selection in Lung Cancer?
EP. 6: Predictive Biomarker Testing for Immunotherapy in Melanoma
EP. 7: Health Plan Coverage of Diagnostic Tests for PD-L1 Expression
EP. 8: Distinguishing Between Companion and Complementary Diagnostic Tests
EP. 9: Clinical Pathways Should Keep Pace With New Data
EP. 10: Health Plan Perspectives on Clinical Pathways
EP. 11: Clinician Concerns with Adopting Clinical Pathways
EP. 12: Safety and Efficacy of Targeted Therapy Versus Immunotherapy in Melanoma
EP. 13: Clinical Pathway Consideration and Payer Decisions
EP. 14: Understanding Immunotherapy Efficacy and Safety
EP. 15: Combination Immunotherapies in Melanoma
EP. 16: Payer Concerns With Including Novel Immunotherapies on Clinical Pathways
EP. 17: Combination Therapies: What Works Best for Immuno-Oncology?
EP. 18: Improving Patient Access-Rapid Approval and Patient Assistance Programs
EP. 19: Health Plan Take on the Cancer Drug Approval Process and Surrogate Endpoints
EP. 20: The Unmet Need in Immuno-Oncology and New Drug Approvals
EP. 21: Value Benchmarks in Immuno-Oncology
EP. 22: Do Oncologists Contemplate Patient Cost Sharing?
EP. 23: Importance of Patient Assistance Programs in Oncology
EP. 24: Payer Stance on Immunotherapy in Oncology Care
EP. 25: Influence of Biomarkers in Immunotherapy Treatment Decisions
EP. 26: Appropriate Use of Companion Versus Complementary Diagnostics
EP. 27: Clinical Pathways
EP. 28: Do Accelerated Review and Narrow Indications Influence Payer Decisions?
EP. 29: The Value of Patient Assistance Programs
2 Clarke Drive Cranbury, NJ 08512